AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia(difelikefalin) as first therapy in Europe for the treatment of
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
18.02.2022 - Presentation to highlight oral difelikefalin Phase 3 pruritus programsSTAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to .
Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as.